Kilitch Drugs Shares Outstanding vs. Gross Profit
| KILITCH Stock | 310.05 3.95 1.29% |
For Kilitch Drugs profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kilitch Drugs to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kilitch Drugs Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kilitch Drugs's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kilitch Drugs Limited over time as well as its relative position and ranking within its peers.
Kilitch |
Kilitch Drugs Limited Gross Profit vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kilitch Drugs's current stock value. Our valuation model uses many indicators to compare Kilitch Drugs value to that of its competitors to determine the firm's financial worth. Kilitch Drugs Limited is currently regarded as number one stock in shares outstanding category among its peers. It also is currently regarded as number one stock in gross profit category among its peers fabricating about 39.91 of Gross Profit per Shares Outstanding. As of now, Kilitch Drugs' Gross Profit is increasing as compared to previous years. Comparative valuation analysis is a catch-all model that can be used if you cannot value Kilitch Drugs by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Kilitch Drugs' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Kilitch Gross Profit vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Kilitch Drugs |
| = | 16.08 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Kilitch Drugs |
| = | 641.83 M |
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Kilitch Gross Profit Comparison
Kilitch Drugs is currently under evaluation in gross profit category among its peers.
Kilitch Drugs Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kilitch Drugs, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kilitch Drugs will eventually generate negative long term returns. The profitability progress is the general direction of Kilitch Drugs' change in net profit over the period of time. It can combine multiple indicators of Kilitch Drugs, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 287.1 M | 301.5 M | |
| Operating Income | 208.1 M | 218.5 M | |
| Income Before Tax | 193.6 M | 203.2 M | |
| Total Other Income Expense Net | -14.5 M | -13.8 M | |
| Net Income | 193.5 M | 203.2 M | |
| Income Tax Expense | 57.8 M | 30.1 M | |
| Net Income From Continuing Ops | 135.8 M | 142.5 M | |
| Net Income Applicable To Common Shares | 120.2 M | 126.2 M | |
| Net Interest Income | -59.3 M | -56.3 M | |
| Interest Income | 56.6 M | 59.4 M | |
| Change To Netincome | 49.6 M | 52.1 M |
Kilitch Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kilitch Drugs. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kilitch Drugs position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kilitch Drugs' important profitability drivers and their relationship over time.
Use Kilitch Drugs in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kilitch Drugs position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kilitch Drugs will appreciate offsetting losses from the drop in the long position's value.Kilitch Drugs Pair Trading
Kilitch Drugs Limited Pair Trading Analysis
The ability to find closely correlated positions to Kilitch Drugs could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kilitch Drugs when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kilitch Drugs - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kilitch Drugs Limited to buy it.
The correlation of Kilitch Drugs is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kilitch Drugs moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kilitch Drugs Limited moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kilitch Drugs can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kilitch Drugs position
In addition to having Kilitch Drugs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Defence Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Kilitch Stock
To fully project Kilitch Drugs' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Kilitch Drugs Limited at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Kilitch Drugs' income statement, its balance sheet, and the statement of cash flows.